Navigation Links
Sustained Viral Response from Phase 2 Studies of BI 201335, Including Difficult-to-Treat HCV Patient Types
Date:11/8/2011

BI 201335 on the background of 24 weeks of PegIFN/RBV was sufficient to achieve sustained viral response (SVR).  Patients with undetectable viral load prior to week 8 had similar SVR rates, whether they were treated for 12 or 24 weeks with BI 201335 (80 percent and 82 percent, respectively).

The most frequent adverse events (AEs) in SILEN-C3 were mild gastrointestinal disorders, rash, photosensitivity and jaundice due to isolated unconjugated hyperbilirubinemia.

In this open-label Phase 2 trial, 159 treatment-naive GT1 HCV patients were randomized to receive 120 mg BI 201335 once daily for 12 or 24 weeks, each after three days lead-in (LI) with PegIFN/RBV.  In both groups, PegIFN/RBV was given for 24 weeks.  Patients who did not have an eRVR continued PegIFN/RBV to week 48.  eRVR was defined as viral load less than 25 IU/mL at week 4 and undetectable at weeks 8-18.  In the 12 week treatment group, 72 percent of patients had an eRVR and in the 24 week treatment group, 82 percent of patients had an eRVR.

(Abstract #226) Treatment with the 2nd Generation HCV Protease Inhibitor BI 201335 Results in High and Consistent SVR Rates – Results from SILEN-C1 in Treatment-Naive Patients Across Different Baseline Factors

This analysis of SILEN-C1 evaluated SVR according to various baseline characteristics among patients who received BI 201335 240 mg once daily without LI.

The majority of patients with more difficult-to-treat HCV types – specifically GT1a and IL-28B non-CC allele patients – achieved SVR.  Among patients with GT1a HCV (n=32), a type that traditionally is associated with lower treatment response rates compared to GT1b, 82 percent achieved SVR.  Among GT1b HCV patients (n=38), 84 percent achieved SVR.  In addition, SVR was 71 percent for patients with non-CC alleles of the IL-28B gene (n=29).  Patients with CC alleles (n=11) or for whom IL-28B genotyping wa
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
4. FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
5. CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date
6. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
7. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
8. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
9. FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
10. Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
11. Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... March 31, 2015 /CNW/ - T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" ... premium quality medical marijuana products and a licensed producer ... Purposes Regulations ( Canada ) ("MMPR"), is ... The Corporation of the District of Saanich ... Company,s premises which now allows for commercial distribution of ...
(Date:3/31/2015)... -- Immune Pharmaceuticals Inc. ("Immune", the "Company") (NASDAQ: ... its planned bullous pemphigoid (BP) clinical development for bertilimumab, ... is an orphan auto-immune blistering disease of the skin ... Europe . As previously announced, ... II clinical trial in Israel ...
(Date:3/31/2015)... , March 31, 2015 ANI Pharmaceuticals, Inc. ... of Propafenone Hydrochloride 150mg, 225mg and 300mg oral tablets, ... The overall US market for Propafenone Hydrochloride 150mg, 225mg ... IMS Health. Arthur S. Przybyl , ... to announce the launch of our fourth product from ...
Breaking Medicine Technology:T-Bird Pharma Inc. Announces Final Municipal Rezoning Approval 2T-Bird Pharma Inc. Announces Final Municipal Rezoning Approval 3Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 2Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 3Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 4ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 2ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 3
... YORK, March 9 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, ... China-based pharmaceutical company,dedicated to improving health through ... range of prescription and over the counter ... initiating a phase one clinical,trial of AOBO-001, ...
... Association (AMA) Foundation announced today the 28 recipients of the 2009 Seed ... to medical students, physician residents and fellows to conduct basic science, applied ... in the following four categories: , , ... HIV/AIDS , ...
Cached Medicine Technology:American Oriental Bioengineering to Initiate a Phase One Clinical Trial in the United States of AOBO-001 Oral Capsule 2American Oriental Bioengineering to Initiate a Phase One Clinical Trial in the United States of AOBO-001 Oral Capsule 3AMA Foundation Announces Seed Grant Research Recipients 2AMA Foundation Announces Seed Grant Research Recipients 3
(Date:3/31/2015)... Illinois (PRWEB) March 31, 2015 ... Visio Stencils Device Library for documenting and diagramming ... following Visio Stencils: , Manufacturer / Device ... PowerEdge r720, Dell PowerEdge r520, Dell PowerEdge r630, ... Power 8 Series, EMC VMAX 100K, VMAX 200K, ...
(Date:3/31/2015)... Indiana (PRWEB) March 31, 2015 ... DeRose in Youngstown, Ohio in 1987. This ... the curve with not just customer satisfaction, but ... been added to the well-stocked arsenal of Yesco ... by American Green Technology® (AGT). The patented environmental ...
(Date:3/31/2015)... 31, 2015 Burns Engineering announces 3-Day Quick ... for the Food & Beverage, Pharmaceutical and Biotech markets. These ... ASME-BPE compliant and are now available as part of Burns’ ... , The S01 and S03 with 1/8” and ... process connections used in process lines 1/4” and larger. ...
(Date:3/31/2015)... 31, 2015 The Heart Fit ... Calgary and surrounding areas. External Counterpulsation is an ... artery disease, specifically stable coronary artery disease. ... is used extensively all over the world for ... Calgarians (Albertans) are extremely fortunate to have the ...
(Date:3/31/2015)... Orlando, FL (PRWEB) March 31, 2015 ... and Sickness Insurance programs, issues a travel advisory to ... Health care costs in the United States are higher ... than even in developed countries. For example, a ... while the same procedure costs about $34,358 . ...
Breaking Medicine News(10 mins):Health News:Altima Adds More Hardware Devices to its NetZoom™ Visio® Stencils Device Library 2Health News:American Green Technology® Signs Exclusive Agreement to Distribute Health Risk Management System in Midwest 2Health News:Burns Engineering Now Offers 3-Day Quick Ship on Sanitary RTDs and Thermocouples 2Health News:New Heart Disease Treatment Called External Counterpulsation (EECP) helps people of Alberta Who Have Failed or Are Not Suitable For Heart Stents or Surgery 2Health News:India Network Foundation issues travel advisory to all US bound travelers on visitor health insurance requirements 2Health News:India Network Foundation issues travel advisory to all US bound travelers on visitor health insurance requirements 3
... is in the process of doing away with a commonly ... phase out the ‘Aropax’ brand of paroxetine and bring in ... used by about 49,000 New Zealanders. ,This move ... maintains that both drugs are the same, except for the ...
... Forest University Baptist Medical Center are helping to lead ... that will test 3,000 patients in an effort to ... patients. ,Though doctors have promoted the value of ... training has not been definitively established as safe in ...
... why we shed tears. But exactly what our tears are made ... study sheds some light on the complex design of tears. What ... made up of three distinct, microscopic layers. The middle, watery layer ... – is sandwiched between a layer of mucus and an outer ...
... is an alarming rise of gambling and gamblers in Britain. ... gambling and casinos then on vegetables and fruits. ... been spent on gambling in United Kingdom. Online gambling has ... time. ,The British medical Association (BMA) has expressed ...
... The death of a 47-year-old man who had worked for ... hundreds of ex-employees, who had also been exposed to toxic ... Thursday, prompting more than 500 protestors, who said he had ... roads and demand an autopsy to assess the possibility of ...
... Plc, Europe's pharmaceutical giant, is finalizing its plan of action, ... Gardasil, in a bid to establish the most effective vaccine ... conducted in the United States, will seek to evaluate the ... to two strains of the human papillomavirus. This virus is ...
Cached Medicine News:Health News:New International Study to Test Exercise in Heart Failure Patients 2Health News:New International Study to Test Exercise in Heart Failure Patients 3Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 2Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 3Health News:Ex-workers Ask HLL to Accept Liability for Mercury Deaths 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: